News
Femtech company Nua is investing in technology to support Indian women
The femtech brand aims to transform women’s wellness in India
Mumbai-based femtech brand Nua aims to “build awareness on intimate and uncomfortable topics ” and support women in India.
Nua seeks to offer Indian women a wellness platform that provides information, products and community support, giving them “uncomplicated, clean and holistic care”.
“We are working towards a one-stop platform encompassing content, community and commerce,” Ravi Ramachandran, the company’s co-founder and CEO, told The Press Trust of India (PTI).
“A lot about women’s wellness is still unknown,” the founder explained. “The idea is to enrich Nua’s bouquet of solutions not just from a product perspective but also build awareness on intimate and uncomfortable topics through informational content.”
The femtech company offers period, skincare and wellness products and uses Amazon Web Services (AWS) for most of its infrastructure needs.
“The real need of the hour is giving both a product solution and also equipping every single woman with the right knowledge regarding her wellbeing,” the CEO said.
“To facilitate this, we are expanding into new distribution channels, enhancing our product portfolio, strengthening our brand marketing and community building efforts while investing deeply in technology that can make wellness uncomplicated and easily accessible.”
Ramachandran added: “The direct-to-consumer (D2C) business model allows us to a great extent to connect directly with our customers, drive our offerings, maintain control over product development, marketing and distribution.
“What is unique to Nua is that we have successfully introduced and sustained a fully customisable auto-repeat subscription plan for our consumers which leads to over 50 per cent of customer retention beyond a period of 12 months.
“This goes on to reinforce the need for a subscription model in this category and high customer satisfaction levels with our period care products.”
Cloud technologies have been key contributors to the infrastructure setup in the technology space over the last few years, Ramachandran explained.
“With Nua, we use AWS for most of our infrastructure needs and it has definitely helped us scale up the infrastructure faster. We have succeeded in establishing a very strong brand in the menstrual wellness space and our endeavour now is to take that forward.
“We will advance deeper and solve more consumer problems within women’s wellness, while managing personalisation at scale. Over time, we will invest in technology to build a one-stop platform that encompasses content, community and commerce.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






